Optimi Health (NASDAQ: OPTH) (CSE: OPTI) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update

Austin, Texas, United States, May 29th, 2026, FinanceWire

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.

Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia’s Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments and supports scaling of psychedelic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi’s GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression.

The company said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opportunities across both public and private payers. Optimi also noted that no serious adverse events have been reported under Australia’s regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what the company describes as the world’s most advanced commercial market for prescribed psilocybin and MDMA therapies.

To view the full press release, visit https://nnw.fm/yYW7j

About Optimi Health Corp.

Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies.

For more information, please visit https://www.optimi.net/

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Contact